In the news: FDA approves the first oral drug for reducing multiple sclerosis relapses

Published: December, 2010

People with relapsing forms of multiple sclerosis (MS) have a new option for reducing periodic attacks (relapses) and for delaying the progression of MS-related disability. MS is typically treated with injected drugs or infusions, which can be painful and inconvenient and may discourage some patients from staying on therapy. The FDA has approved the first oral medication, fingolimod, brand name Gilenya (pronounced jil-EN-yah).

The drug, taken once a day in 0.5-milligram (mg) capsules, works by a different mechanism than other approved MS medications, and in a head-to-head comparison, it was more effective against relapses than one of the leading injectables. However, fingolimod has a number of side effects — some potentially quite serious — and its long-term safety and effectiveness are unknown.

To continue reading this article, you must log in.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise

New subscriptions to Harvard Health Online are temporarily unavailable. Click the button below to learn about our other subscription offers.

Learn More »